Immunogenicity and antimicrobial effectiveness of Pseudomonas aeruginosa specific bacteriophage in a human lung in vitro model

Applied Microbiology and Biotechnology

Volumn 101, Issue 21, 2017, Pages 7977-7985

  Shiley, Joseph R ^a   Comfort, Kristen K ^b   Robinson, Jayne B ^a  

^a UNIVERSITY OF DAYTON   (United States)

^b University of Dayton   (United States)

Author keywords

Bacteriophage therapy; Cytokine production; Immune response; Lung co culture model; Pseudomonas aeruginosa

Indexed keywords

BACTERIA; BIOCOMPATIBILITY; BIOLOGICAL ORGANS; HEALTH RISKS; MAMMALS;

ANTIBIOTIC-RESISTANT BACTERIA; BACTERIAL INFECTIONS; CO-CULTURES; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNOLOGICAL RESPONSE; PSEUDOMONAS AERUGINOSA; RECEPTOR EXPRESSION;

BACTERIOPHAGES;

ANTIBIOTIC AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PILIN; TUMOR NECROSIS FACTOR;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL DISEASE; BACTERIOPHAGE; BACTERIUM; BIOTECHNOLOGY; HORMONE; IMMUNE RESPONSE; IMMUNE SYSTEM; LABORATORY METHOD; MODEL;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; INNATE IMMUNITY; LUNG ALVEOLUS CELL; NONHUMAN; PHAGE THERAPY; PSEUDOMONAS AERUGINOSA; RECEPTOR BINDING; UPREGULATION; A-549 CELL LINE; BIOLOGICAL MODEL; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; PNEUMONIA; PROCEDURES; PSEUDOMONAS INFECTION; PSEUDOMONAS PHAGE; SECRETION (PROCESS); TREATMENT OUTCOME; VIROLOGY;

BACTERIA (MICROORGANISMS); MAMMALIA; PSEUDOMONAS AERUGINOSA;

A549 CELLS; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-6; MODELS, BIOLOGICAL; PHAGE THERAPY; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85029535573     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-017-8504-1     Document Type: Article

References (53)

1. Abedon ST, Thomas-Abedon C (2010) Phage therapy pharmacology. Curr Pharm Biotechnol 11:28–47
2. Balin BJ, Hammond CJ (2012) Emerging viral and bacterial infections of the central nervous system. Neurobehav HIV Med 2012:35–44
3. Belkaid Y, Hand TW (2014) Role of mirobiota in immunity and inflammation. Cell 157:121–141
4. Berendonk TU, Manaia CM, Merlin C, Fatta-Kassinos D, Cytryn E, Walsh F, Burgmann H, Sorum H, Norstrom M, Pons MN, Kreuzinger N, Houvinen P, Stefani S, Schwartz T, Kisand V, Baquero F, Martinez JL (2015) Tackling antibiotic resistance: the environmental framework. Nat Rev Microbiol 13:310–317
5. Betts A, Vasse M, Kaltz O, Hochberg ME (2013) Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PA01. Evol Appl 6:1054–1063
6. Bonilla N, Rojas MI, NettoFCG HSH, Rohwer F, Barr JJ (2016) Phage on tap—a quick and efficient protocol for the preparation of bacteriophage laboratory stocks. Peer J 4:e2261
7. Bosch ATM, Biesbroek G, Trzcinski K, Sanders EAM, Bogaert D (2013) Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog 9:e1003057
8. Braun NJ, DeBrosse MC, Hussain SM, Comfort KK (2016) Modification of the protein corona-nanoparticle complex by physiological factors. Mat Sci Eng C 64:34–42
9. Braydich-Stolle LK, Speshock JL, Castle A, Smith M, Murdock RC, Hussain SM (2010) Nanosized aluminum altered immune function. ACS Nano 4:3661–3670
10. Breitner EK, Hussain SM, Comfort KK (2015) The role of biological fluid and dynamic flow in the behavior and cellular interactions of gold nanoparticles. J Nanobiotechnol 13:56
11. Brüssow H (2005) Phage therapy: the Escherichia coli experience. Microbiol 151:2133–2140
12. Brüssow H (2012) What is needed for phage therapy to become a reality in Western medicine? Virology 434:138–142
13. Brüssow H (2017) Phage therapy for the treatment of human intestinal bacterial infections: soon to be a reality? Expert Rev Gastroenterol Hepatol. https://doi.org/10.1080/17474124.2017.1342534
14. Brüssow H, Canchaya C, Hardt WD (2004) Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microb Mol Biol Rev 68:560–602
15. Budzik JM, Rosche WA, Rietsch A, O’Toole GA (2004) Isolation and characterization of a generalized transducing phage for Pseudomonas aeruginosa strains PAO1 and PA14. J Bacteriol 186:3270–3273
16. Ceyssens PJ, Mesyanzhinov V, Sykilinda N, Briers Y, Roucourt B, Lavigne R, Robben J, Domashin A, Miroshnikov K, Volckaert G, Hertveldt K (2007) The genome and structural proteome of YuA, a new Pseudomonas aeruginosa phage resembling M6. J Bacteriol 190:1429–1435
17. Ceyssens PJ, Brabban A, Rogge L, Lewis MS, Pickard D, Goulding D, Dougan G, Noben JP, Kropinski A, Kutter E, Lavignea R (2010) Molecular and physiological analysis of three Pseudomonas aeruginosa phages belonging to the “N4-like viruses”. Virology 405:26–30
18. Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL (2015) New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 70:3291–3297
19. Chevalier J, Bredin J, Mahamoud A, Mallea M, Barbe J, Pages JM (2004) Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrob Agents Chemother 48:1043–1046
20. Collins TL, Markus EA, Hassett DJ, Robinson JB (2010) The effect of a cationic porphyrin on Pseudomonas aeruginosa biofilms. Curr Microbiol 61:411–416
21. De Smet J, Zimmermann M, Kogadeeva M, Ceyssens PJ, Vermaelen W, Blasdel B, Jang HB, Sauer U, Lavigne R (2016) High coverage metabolomics analysis reveals phage-specific alterations to Pseudomonas aeruginosa physiology during infection. ISME J 10:1823–1835
22. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L (2010) Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 201:1096–1104
23. Del Alamao JC, Lemons D, Serrano R, Savchenko A, Cerignoli F, Bodmer R, Mercola M (2016) High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. Biochim Biophys Acta 1863:1717–1727
24. Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre AS, Lavigne R (2012) Learning from bacteriophages—advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci 13:699–722
25. Dubern JF, Cigana C, De Simone M, Lazenby J, Juhas M, Schwager S, Bianconi I, Döring G, Eberl L, Williams P, Bragonzi A, Cámara M (2015) Integrated whole-genome screening for Pseudomonas aeruginosa virulence genes using multiple disease models reveals that pathogenicity is host specific. Environ Microbiol 17:4379–4393
26. Duque GA, Descoteaux A (2014) Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol 5:491
27. Ellis AE (2001) Innate host defense mechanisms of fish against viruses and bacteria. Environ Microbiol 17:4379–4393
28. Fabrega A, Madurga S, Giralt E, Vila J (2009) Mechanism of action of and resistance to quinolones. Microb Biotechnol 2:40–61
29. de la Fuente-Nunez C, Reffuveille F, Fernandez L, Hancock RE (2013) Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol 16:580–589
30. Harrison F, Diggle SP (2016) An ex vivo lung model to study bronchioles infected with Pseudomonas aeruginosa biofilms. Microbiology 162:1755–1760
31. Hoelting L, Scheinhardt B, Bondarenko O, Schildknecht S, Kapitza M, Tanavde V, Tan B, Lee QY, Mecking S, Leist M, Kadereit S (2015) A 3-dimensional embryonic stem cell (hESC)-derived model to detect developmental neurotoxicity of nanoparticles. Arch Toxicol 87:721–733
32. Hoffmann N, Rasmussen TB, Jensen PO, Stub C, Hentzer M, Molin S, Ciofu O, Givskov M, Johansen HK, Høiby N (2005) A novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun 73:2504–2514
33. Hraiech S, Bregeon F, Rolain JM (2015) Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des Devel Ther 9:3653–3663
34. Jacobs MA, Alwood A, Thaipisuttikul I, Spencer D, Haugen E, Ernst S, Will O, Kaul R, Raymond C, Levy R, Chung-Rong L, Guenthner D, Bovee D, Olson MV, Manoil C (2003) Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 100:14339–14344
35. Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP (2009) Enumeration of bacteriophages by double agar overlay plaque assay. Methods Mol Biol 501:69–76
36. Langton-Hewer SCL, Smyth AR (2014) Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 11:CD004197
37. Loc-Carrillo C, Abedone ST (2011) Pros and cons of phage therapy. Bacteriophage 1:111–114
38. Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Gorski A (2007) Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig Med Dosw 61:461–465
39. Mirzaei MK, Haileselassie Y, Navis M, Cooper C, Sverremark-Ekstrom E, Nilsson AS (2016) Morphologically distinct Escherichia coli bacteriophages differ in their efficacy and ability to stimulate cytokine release in vitro. Front Microbiol 7:437
40. Morello E, Sausseraeu E, Maura D, Mi H, Touqui L, Debarbieux L (2011) Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: steps towards treatment and prevention. PLoS One 6:e16963
41. Osiecki H (2004) The role of chronic inflammation in cardiovascular disease and its regulation by nutrients. Altern Med Rev 9:32–53
42. Panacek A, Smekalova M, Vecerova R, Bogdanova K, Roderova M, Kolar M, Kilianova M, Hradilova S, Froning JP, Havrdova M (2016) Silver nanoparticles strongly enhance and restore bactericidal activity of inactive antibiotics against multiresistant Enterobacteriaceae. Colloids Surf B Biointerfaces 142:392–399
43. Piddock LJV (2012) The crisis of no new antibiotics—what is the way forward? Lancet Inf Dis 12:249–253
44. Poranen MM, Ravantti JJ, Grahn AM, Gupta R, Auvinen P, Bamford DH (2006) Global changes in cellular gene expression during bacteriophage PRD1 infection. J Virol 80:8081–8088
45. Reardon S (2014) Phage therapy gets revitalized: the rise of antibiotic resistance rekindles interest in a century-old virus treatment. Nature 510:15–17
46. Spellberg B, Bartlett JG, Gilbert DN (2013) The future of antibiotics and resistance. N Engl J Med 368:299–302
47. Tang H, Kays M, Prince A (1995) Role Pseudomonas aeruginosa pili in acute pulmonary infection. Infect Immun 63:1278–1285
48. Valencia PM, Farokhzad OC, Karnik R, Langer R (2012) Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol 7:623–629
49. Winstanley C, O'Brien S, Brockhurst MA (2016) Pseudomonas aeruginosa evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol 24:327–337
50. Yoho J, Wogensthal K, Bennett TL, Palmer J, Comfort KK, Kango-Singh M, Swavey SS, Stuart CH, Gmeiner WH (2017) Water-soluble zinc porphyrin capable of light-induced photocleavage of DNA: cell localization studies in Drosophila melanogaster and light activated treatment of lung cancer cells. Eur J Inorg Chem 2017:153–159
51. Yosef I, Manor M, Kiro R, Qimron U (2015) Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci U S A 112:7267–7272
52. Zegans ME, Wagner JC, Cady KC, Murphy DM, Hammond JH, O’Toole GA (2009) Interactions between bacteriophages DMS3 and host CRISPR region inhibits group behaviors of Pseudomonas aeruginosa. J Bacteriol 2009:210–219
53. Zimecki J, Kocieba M, Weber-Dabrowska B, Borysowski J, Gorski A (2009) Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus. BMC Microbiol 9:169